Xenadrine EFX refunds
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission will accept refund requests through Sept. 15 from consumers who were not satisfied with the product after buying it between Feb. 1, 2002 and May 22, 2006, the agency said in an Aug. 6 release. Under a settlement announced Jan. 4, Xenadrine EFX marketers Robert Chinery Jr., Tracey Chinery and RTC Research & Development LLC were required to pay as much as $12.8 million for consumer refunds after FTC alleged the product's weight-loss claims were false and unsubstantiated. Xenadrine EFX includes green tea extract and other caffeine sources (1"The Tan Sheet" Jan. 8, 2007, p. 4)...
You may also be interested in...
Xenadrine EFX manufacturer settles with FTC
RTC Research and Development and the company's executives, husband and wife Robert Chinery Jr. and Tracy Chinery, settle in a case brought by the Federal Trade Commission for charges of false and unsubstantiated weight-loss claims related to their supplement Xenadrine EFX. In an April 24 release. FTC says it charged the defendants in 2005, and in 2006 the U.S. District Court for the District of New Jersey barred Robert Chinery and RTC from making claims and required RTC pay $8 million in consumer redress (1"The Tan Sheet" Aug. 13, 2007, In Brief). Tracy Chinery's motion to dismiss a similar settlement was denied in July 2007 and her motion for summary judgment was denied in March 2009, FTC says. The final settlement prohibits the Manasquan, N.J.-based firm and the Chinerys from "making any claims about the health benefits, performance, efficacy, safety, or side effects of any weight-loss product, dietary supplement, food, drug, or device" unless substantiated, true and not misleading. FTC says the defendants are not required to provide additional redress
FTC Supplement Settlements Spotlight Bayer, Mark First Hoodia Action
Bayer "went too far" with weight-loss and -control claims for its One-A-Day WeightSmart product and violated a 1991 sanction the product's previous owner agreed to, the Federal Trade Commission said Jan. 4 when it announced a record $3.2 million fine against the consumer healthcare giant
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.